Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

86.24 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 456
Open 86.24
Bid (Size) 84.60 (100)
Ask (Size) 93.75 (600)
Prev. Close 86.24
Today's Range 86.24 - 86.24
52wk Range 14.00 - 102.06
Shares Outstanding 101,192,921
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
From Spyre Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+182.0%
+182.0%
1 Month
+17.1%
+17.1%
3 Month
+88.8%
+88.8%
6 Month
+160.9%
+160.9%
1 Year
+459.6%
+459.6%

More News

Read More
News headline image
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
Via The Motley Fool
News headline image
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Spyre Therapeutics, Inc. - Common Stock publicly traded?
Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?
Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?
The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market
What is the current price of Spyre Therapeutics, Inc. - Common Stock?
The current price of Spyre Therapeutics, Inc. - Common Stock is 86.24
When was Spyre Therapeutics, Inc. - Common Stock last traded?
The last trade of Spyre Therapeutics, Inc. - Common Stock was at 06/24/26 04:00 PM ET
What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?
The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 8.73B
How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?
Spyre Therapeutics, Inc. - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.